Literature DB >> 12777075

Repetitive 5-aminolevulinic acid-mediated photodynamic therapy on human glioma spheroids.

Steen J Madsen1, Chung-Ho Sun, Bruce J Tromberg, Henry Hirschberg.   

Abstract

The response of human glioma spheroids to repetitive 5-aminolevulinic acid-mediated photodynamic therapy (PDT) was investigated. In all cases, light fluences were kept below toxic thresholds to simulate conditions typically found at 1-2 cm depths in brain adjacent to tumor. Significant inhibition of spheroid growth was observed following multiple PDT treatments at sub-threshold light fluences. The effect appears to be insensitive to the treatment intervals investigated (weekly or bi-monthly). In all cases, suppression of growth was observed for the duration of treatment. Low fluence rates (< or = 5 mW cm(-2)) appear to be more effective than high fluence rates (25 mW cm(-2)). No evidence of PDT resistance was found in this investigation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12777075     DOI: 10.1023/a:1023362011705

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  34 in total

1.  In vitro and in vivo porphyrin accumulation by C6 glioma cells after exposure to 5-aminolevulinic acid.

Authors:  W Stummer; S Stocker; A Novotny; A Heimann; O Sauer; O Kempski; N Plesnila; J Wietzorrek; H J Reulen
Journal:  J Photochem Photobiol B       Date:  1998-09       Impact factor: 6.252

2.  Intraoperative detection of malignant gliomas by 5-aminolevulinic acid-induced porphyrin fluorescence.

Authors:  W Stummer; S Stocker; S Wagner; H Stepp; C Fritsch; C Goetz; A E Goetz; R Kiefmann; H J Reulen
Journal:  Neurosurgery       Date:  1998-03       Impact factor: 4.654

3.  The effect of fluence rate on tumor and normal tissue responses to photodynamic therapy.

Authors:  T M Sitnik; B W Henderson
Journal:  Photochem Photobiol       Date:  1998-04       Impact factor: 3.421

Review 4.  5-Aminolevulinic acid-based photodynamic therapy: principles and experimental research.

Authors:  Q Peng; K Berg; J Moan; M Kongshaug; J M Nesland
Journal:  Photochem Photobiol       Date:  1997-02       Impact factor: 3.421

Review 5.  5-Aminolevulinic acid-based photodynamic therapy. Clinical research and future challenges.

Authors:  Q Peng; T Warloe; K Berg; J Moan; M Kongshaug; K E Giercksky; J M Nesland
Journal:  Cancer       Date:  1997-06-15       Impact factor: 6.860

Review 6.  Photodynamic therapy.

Authors:  T J Dougherty
Journal:  Photochem Photobiol       Date:  1993-12       Impact factor: 3.421

7.  Optical properties of human brain.

Authors:  L O Svaasand; R Ellingsen
Journal:  Photochem Photobiol       Date:  1983-09       Impact factor: 3.421

8.  Influence of fractionation and fluence rate in photodynamic therapy with Photofrin or mTHPC.

Authors:  I P van Geel; H Oppelaar; J P Marijnissen; F A Stewart
Journal:  Radiat Res       Date:  1996-05       Impact factor: 2.841

9.  Apoptosis induced in vivo by photodynamic therapy in normal brain and intracranial tumour tissue.

Authors:  L Lilge; M Portnoy; B C Wilson
Journal:  Br J Cancer       Date:  2000-10       Impact factor: 7.640

10.  Uptake and kinetics of 14C-labelled meta-tetrahydroxyphenylchlorin and 5-aminolaevulinic acid in the C6 rat glioma model.

Authors:  A Obwegeser; R Jakober; H Kostron
Journal:  Br J Cancer       Date:  1998-09       Impact factor: 7.640

View more
  8 in total

Review 1.  Mechanisms of resistance to photodynamic therapy.

Authors:  A Casas; G Di Venosa; T Hasan
Journal:  Curr Med Chem       Date:  2011       Impact factor: 4.530

2.  Acute morphological sequelae of photodynamic therapy with 5-aminolevulinic acid in the C6 spheroid model.

Authors:  Pitr Zelenkov; Reinhold Baumgartner; Karl Bise; Michael Heide; Richard Meier; Susanne Stocker; Ronald Sroka; Roland Goldbrunner; Walter Stummer
Journal:  J Neurooncol       Date:  2006-09-27       Impact factor: 4.130

Review 3.  Site-specific opening of the blood-brain barrier.

Authors:  Steen J Madsen; Henry Hirschberg
Journal:  J Biophotonics       Date:  2010-06       Impact factor: 3.207

4.  Protection of crayfish glial cells but not neurons from photodynamic injury by nerve growth factor.

Authors:  A V Lobanov; A B Uzdensky
Journal:  J Mol Neurosci       Date:  2009-04-18       Impact factor: 3.444

5.  Disruption of the blood-brain barrier following ALA-mediated photodynamic therapy.

Authors:  Henry Hirschberg; Francisco A Uzal; David Chighvinadze; Michelle J Zhang; Qian Peng; Steen J Madsen
Journal:  Lasers Surg Med       Date:  2008-10       Impact factor: 4.025

6.  The effects of ultra low fluence rate single and repetitive photodynamic therapy on glioma spheroids.

Authors:  Marlon S Mathews; Even Angell-Petersen; Rogelio Sanchez; Chung-Ho Sun; Van Vo; Henry Hirschberg; Steen J Madsen
Journal:  Lasers Surg Med       Date:  2009-10       Impact factor: 4.025

7.  Motexafin gadolinium enhances the efficacy of aminolevulinic acid mediated-photodynamic therapy in human glioma spheroids.

Authors:  Steen J Madsen; Marlon S Mathews; Even Angell-Petersen; Chung-Ho Sun; Van Vo; Rogelio Sanchez; Henry Hirschberg
Journal:  J Neurooncol       Date:  2008-09-06       Impact factor: 4.130

8.  Intracellular chemiluminescence activates targeted photodynamic destruction of leukaemic cells.

Authors:  R Laptev; M Nisnevitch; G Siboni; Z Malik; M A Firer
Journal:  Br J Cancer       Date:  2006-07-04       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.